Saving changes...

Done

Error

Practical experience of administering subcutaneous rituximab

Practical experience of administering subcutaneous rituximab

Practical experience of administering subcutaneous rituximab

Sarah Liptrott, Nicola Crosbie, Maris Stella Sugino, Renate Bratke, Maria Mendoza, and Pakeeza Sayye
Sarah Liptrott, Nicola Crosbie, Maris Stella Sugino, Renate Bratke, Maria Mendoza, and Pakeeza Sayye
on behalf of Royal College of Nursing

$30.00 $ 30.00 $ 30.00

$30.00 $ 30.00 $ 30.00

$ 30.00 $ 30.00 $ 30.00
$ 30.00 $ 30.00 $ 30.00
Normal Price: $30.00 $30.00

Review:

Launch date: 26 Jan 2018
Expiry Date:

Last updated: 19 Dec 2018

Reference: 186250

This course is no longer available

Exam is embedded in the course
No preview available
No Exam Available

Latest User Comments

Mrs Jodie Deakin (16 Sep 2018)
Brilliant resource for learning about Rituximab S/C.

I would like to...

Course Availability

This course is only available to trainees days after purchase. It would need to be repurchased by the trainee if not completed in the allotted time period. This course is no longer available. You will need to repurchase if you wish to take the course again.

Description

Treatment regimens involving the monoclonal anti-CD20 antibody rituximab are the standard of care for patients with CD20-positive non-Hodgkin lymphoma (NHL). It has conventionally been given by intravenous (IV) infusion, which requires intermittent patient monitoring during administration. A subcutaneous (SC) formulation is also available for the treatment of NHL, which takes less time to administer and could simplify treatment. With the newer formulation available, there is an ongoing need for education and understanding from the patient’s and the healthcare professional’s perspective. The authors review their personal experience of rituximab IV and SC formulations together with data on their safety, and provide an overview of the use of SC formulation in daily nursing practice.

Objectives

After reading this module you should be able to:
• Describe how rituximab works in patients with non-Hodgkin lymphoma (NHL).
• Access the clinical guidance available for patient assessment and preparation for SC administration and understand how to administer the SC injection.
Sarah Liptrott, Nicola Crosbie, Maris Stella Sugino, Renate Bratke, Maria Mendoza, and Pakeeza Sayye

Author Information Play Video Bio

Sarah Liptrott, Nicola Crosbie, Maris Stella Sugino, Renate Bratke, Maria Mendoza, and Pakeeza Sayye
on behalf of Royal College of Nursing

Sarah Liptrott, Clinical research nurse, European Institute of Oncology, Milan, Italy.

Nicola Crosbie, Nurse clinician, Derriford Hospital, Plymouth Hospitals NHS Trust.

Maris Stella Sugino, Nurse clinician, Hospital das Clínicas da FMUSP, São Paulo, Brazil.

Renate Bratke, Nurse clinician, Technical University Munich, Germany.

Maria Mendoza, International scientific director, F Hoffmann-La Roche Ltd, Basel, Switzerland.

Pakeeza Sayyed, Senior clinical scientist, F Hoffmann-La Roche Ltd, Basel, Switzerland.

Current Accreditations

This course has been certified by or provided by the following Certified Organization/s:

  • Royal College of Nursing (RCN)
  • 1.00 Hours

Faculty and Disclosures

Additional Contributors

Conflicts Declared

Conflicts of Interest declaration by Author:

null

User Reviews (1)

Go Back
Mrs Jodie Deakin (16 Sep 2018)
Brilliant resource for learning about Rituximab S/C.

Loading...


Saving changes...

Done

Error